Duodenal Mucosal Resurfacing (DMR)

DEVICE4 trials

Sponsors

Fractyl Health Inc., Cleveland Clinic London

Conditions

Diabetes Mellitus, Type 2ObesityType 2 Diabetes

Unknown Phase

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

CompletedNCT03653091

Fractyl Health Inc.Type 2 Diabetes

Start: 2018-09-28End: 2020-08-10Updated: 2024-02-14

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

SuspendedNCT04419779

Fractyl Health Inc.Type 2 Diabetes

Start: 2021-03-08End: 2026-01-31Target: 320Updated: 2025-11-13

A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes

SuspendedNCT06256497

Fractyl Health Inc.Diabetes Mellitus, Type 2

Start: 2023-06-27End: 2028-12-01Target: 100Updated: 2025-03-14

A UK Registry for Metabolic and Bariatric Endoscopic Interventions

RecruitingNCT06305208

Cleveland Clinic LondonDiabetes Mellitus, Type 2, Obesity

Start: 2024-02-01End: 2039-02-01Target: 300Updated: 2024-03-15

Related Papers

Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study.

2024-01-258 citations

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial

Gut2021-02-17104 citations